Neuroleptic-Induced Catatonia as a Stage in the Progression Toward NMS
J Am Acad Child Adolesc Psychiatry 31:1161-1164, Woodbury,M.M.&Woodbury,M.A., 1992
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
Susceptibility to Neuroleptic Malignant Syndrome in Parkinson's Disease
Neurol 52:777-781, Ueda,M.,et al, 1999
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998
Epileptic Seizures in Patients with Acute Catatonic Syndrome
JNNP 57:1419-1422, Primavera,A.,et al, 1994
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
The Neuroleptic Malignant Syndrome
Arch Int Med 142:1183-1185, Smego,R.A.,et al, 1982